{
  "first_published_at": "2012-03-08", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON146532", 
  "title": "Unlicensed imported vitamin D (colecalciferol) capsules: potential peanut oil and soya oil allergens", 
  "tags": "{\"parsed_therapeutic\": [\"nutrition-dietetics\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Nutrition and dietetics\"]}", 
  "_document_number": 119, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "nutrition-dietetics"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Unlicensed imported vitamin D (colecalciferol) capsules: potential peanut oil and soya oil allergens</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: March 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Healthcare professionals should be aware that these capsules contain potential allergens and are contraindicated in patients with relevant allergies-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Vigantoletten and Dekristol vitamin D (colecalciferol) capsules are unlicensed medicines in the UK. However, they are legitimately imported and supplied in their original German language livery for the special needs of individual patients only on prescription under the direct responsibility of the prescriber. The German labelling of these products states that Vigantoletten capsules contain soya oil, and that Dekristol capsules contain arachis (peanut) oil. This is unlikely to be evident to non-German speakers. Healthcare professionals should be aware that these capsules contain potential allergens.</p>\n\n<p>Furthermore, imported unlicensed vitamin D Osto D2 capsules from Canada and Drisdol capsules from the USA may pose a similar allergen risk. Although labelled in English, the products may not explicitly state that they contain soya oil.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Allergy to soya oil or arachis oil may lead to severe allergic reactions, including anaphylaxis</li>\n\n<li>These products are contraindicated in patients with relevant allergies. Doctors and pharmacists should enquire whether patients have any relevant allergies before supplying these medicines</li>\n\n<li>Importers are advised that prescribers must be made aware of this contraindication</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>Drug safety information <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON140798\">for Vigantoletten capsules</a></p>\n\n<p>Drug safety information <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON140797\">for Dekristol capsules</a></p>\n\n<p>Unlicensed or off-label use of medicines: <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087990\">prescribers&#8217; responsibilities</a> &#160;</p>\n\n<p><em>Article citation: Drug Safety Update March 2012, vol 5 issue 8: S2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Vigantoletten and Dekristol vitamin D (colecalciferol) capsules are unlicensed medicines in the UK. However, they are legitimately imported and supplied in their original German language livery for the special needs of individual patients only on prescription under the direct responsibility of the prescriber. The German labelling of these products states that Vigantoletten capsules contain soya oil, and that Dekristol capsules contain arachis (peanut) oil. This is unlikely to be evident to non-German speakers. Healthcare professionals should be aware that these capsules contain potential allergens.</p>\n\n<p>Furthermore, imported unlicensed vitamin D Osto D2 capsules from Canada and Drisdol capsules from the USA may pose a similar allergen risk. Although labelled in English, the products may not explicitly state that they contain soya oil.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Allergy to soya oil or arachis oil may lead to severe allergic reactions, including anaphylaxis</li>\n\n<li>These products are contraindicated in patients with relevant allergies. Doctors and pharmacists should enquire whether patients have any relevant allergies before supplying these medicines</li>\n\n<li>Importers are advised that prescribers must be made aware of this contraindication</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>Drug safety information <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON140798\">for Vigantoletten capsules</a></p>\n\n<p>Drug safety information <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON140797\">for Dekristol capsules</a></p>\n\n<p>Unlicensed or off-label use of medicines: <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087990\">prescribers&#8217; responsibilities</a> &#160;</p>\n\n<p><em>Article citation: Drug Safety Update March 2012, vol 5 issue 8: S2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-03-01", 
  "date_last_modified": "2012-03-08", 
  "_assets": [], 
  "_item_id": 119, 
  "summary": "", 
  "body": "Article date: March 2012\n\nVigantoletten and Dekristol vitamin D (colecalciferol) capsules are unlicensed medicines in the UK. However, they are legitimately imported and supplied in their original German language livery for the special needs of individual patients only on prescription under the direct responsibility of the prescriber. The German labelling of these products states that Vigantoletten capsules contain soya oil, and that Dekristol capsules contain arachis (peanut) oil. This is unlikely to be evident to non-German speakers. Healthcare professionals should be aware that these capsules contain potential allergens.\n\nFurthermore, imported unlicensed vitamin D Osto D2 capsules from Canada and Drisdol capsules from the USA may pose a similar allergen risk. Although labelled in English, the products may not explicitly state that they contain soya oil.\n\nAdvice for healthcare professionals:  \n  \n  * Allergy to soya oil or arachis oil may lead to severe allergic reactions, including anaphylaxis  \n  * These products are contraindicated in patients with relevant allergies. Doctors and pharmacists should enquire whether patients have any relevant allergies before supplying these medicines  \n  * Importers are advised that prescribers must be made aware of this contraindication  \n  \nFurther information:\n\nDrug safety information [for Vigantoletten capsules](http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON140798)\n\nDrug safety information [for Dekristol capsules](http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON140797)\n\nUnlicensed or off-label use of medicines: [prescribers’ responsibilities](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087990)  \n\nArticle citation: Drug Safety Update March 2012, vol 5 issue 8: S2.\n"
}